• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search

Home

Harnessing the Power of the Microbiome to Revolutionize Treatment of Disease

Rebiotix Inc., a Ferring Company, is a clinical stage biotechnology company founded to revolutionize the treatment of debilitating diseases by harnessing the power of the human microbiome.

This new and swiftly expanding field continues to underscore the powerful connection between the human microbiome and health, and how restoring disrupted microbiomes, particularly those of the human gut, may be needed to combat challenging diseases1.

Driven to help people live better lives

Through strong science and careful clinical evaluation, we aim to develop microbiota-based live biotherapeutics that bring the potential of the human microbiome to the patients and physicians who need them most.

In 2018, Rebiotix joined Ferring Pharmaceuticals, a globally-recognized specialty pharmaceutical company driven to help people live better lives. Combined with their history and passion for microbiome-based research, our ability to make microbiota-based live biotherapeutics may soon be a reality.

The Leader in Developing Microbiota-Based Therapies through the MRT™ Drug Platform

The MRT platform is our technology for developing formulations consisting of live, human-derived microbes.

We have the most advanced human clinical program with extensive clinical trial experience in multiple indications, evaluating an investigative microbiota-based live biotherapeutic drug. Our research, conducted in coordination with regulatory authorities, encompasses studies with acute and chronic disease states through both company- and physician-sponsored trials. Check out our clinical program, including our advanced investigative programs for recurrent Clostridioides difficile infection, for more information.


NEWS & PRESS RELEASES

11.30.22: Ferring Receives U.S. FDA Approval for REBYOTA™ (fecal microbiota, live-jslm) – A Novel First-in-Class Microbiota-Based Live Biotherapeutic

read more

UPCOMING MEETING

DDW 2022
May 21-24

Visit Site

FOLLOW @REBIOTIX

Rebiotix Inc. @rebiotix ·
16 Nov

The 7th Annual #MicrobiomeConnectUSA begins today, and our @Rebiotix CSO and @Ferring VP of Microbiome Research, @KenBlountPhD, will be presenting some fascinating information on the #mightymicrobiome. Attending? Be sure and add these sessions to your agenda! #FerringMicrobiome

@rebiotix

References

  1. Blount KF et al. Restoration of Bacterial Microbiome Composition and Diversity Among Treatment Responders in a Phase 2 Trial of RBX2660: An Investigational Microbiome Restoration Therapeutic. Open Forum Infectious Diseases. 2019;6(4). doi:10.1093/ofid/ofz095

Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us